Bayer Pharmaceuticals Archives - Carey Danis & Lowe

Yaz Lawsuit Cites Bayer’s Lack of Blood Clot Risk Warning

By | Pharmaceutical litigation, Uncategorized, Yaz/Yasmin

yaz_lawsuit_yasmin_side_effects_lawsuits_dvt_blood_clot_settlementsIn early September, a woman who suffered from a deep vein thrombosis (DVT) in her right leg two years ago filed a Yaz lawsuit. According to a recent article in The Pennsylvania Record, the plaintiff, Dana Dougherty, filed her Yaz lawsuit alleging that the hormone present in Yaz, drospirenone, led to her health problems.

The lawsuit goes on to claim that the maker of Yaz, Bayer Pharmaceuticals, put the oral contraceptive on the market neglecting to include proper warnings about the risks of blood clots, DVT, and other serious side effects.

In a warning released by the U.S. Food and Drug Administration (FDA) in April 2012, they provided information about the association between oral contraceptives that contain the hormone drospirenone, such as Yaz and Yasmin, and the increased risk of developing a blood clot. The FDA pointed out that, according to currently available information, blood clot formation has a stronger link to drospirenone oral contraceptives than oral contraceptives that contain other types of hormones.

The British Medical Journal published an oft-cited study in August 2009 about the increased risk of blood clot development in patients using different types of oral contraceptives. When looking at patients using an oral contraceptive containing drospirenone, the researchers recorded a six-fold increase in the risk of blood clot formation when compared to individuals not using an oral contraceptive.

Researchers have also reported a considerably increased risk of blood clot formation and other venous complications during the first six months of using a drospirenone-containing oral contraceptive like Yaz, Yasmin, or Ocella.

As a national law firm that represents women who claim to have been injured by the use of Yaz, Yasmin, or Ocella, Carey Danis & Lowe has provided expert legal counsel in numerous cases that cite similar claims about insufficient warning about blood clot risks.

In addition to the risk of blood clot formation, plaintiffs who have filed Yaz and Yasmin lawsuits have also linked the oral contraceptives to heart attack, stroke, brain hemorrhage, and pulmonary embolism.

Carey Danis & Lowe Yaz and Yasmin lawyers are currently taking cases. For a free legal evaluation and to speak with one of our medical experts, contact Carey Danis & Lowe today to learn about your legal options.

Share your story with Carey Danis & Lowe by calling us at 800.721.2519, or by submitting a personal injury claim form.

Federal Trade Commission Concludes Investigation into Bayer Pharmaceuticals and Yasmin Patent Litigation

By | Pharmaceutical litigation, Uncategorized, Yaz/Yasmin

Published October 12, 2012 by LawsuitInformation.org

Federal Trade Commission Concludes Investigation into Bayer Pharmaceuticals and Yasmin Patent LitigationIn recent news regarding Bayer Pharmaceuticals, the German pharmaceutical giant responsible for the manufacture of Yaz and Yasmin, the Federal Trade Commission made the decision to terminate its investigation into a patent settlement between Bayer and Teva Pharmaceuticals.

In 2008, the two pharmaceutical companies reached an agreement in regards to Bayer’s claim that Barr Laboratories, which was ultimately purchased by Teva Pharmaceuticals, overstepped the boundaries of intellectual property protecting Bayer’s Yasmin patent. The 2008 settlement drew the attention of the FTC, and led to a four year investigation into the settlement agreement’s possible antitrust violations.

Though the investigation has ended, Bayer Pharmaceuticals is still tied up in a Multi-District Litigation in the Southern District of Illinois regarding a large number of Yaz and Yasmin lawsuits.

The U.S. Food and Drug Administration released data last October 2011 regarding a Yaz and Yasmin study they conducted in order to determine the drug’s link to the development of blood clots in women. The FDA’s research indicated that among the approximately 800,000 women, they recorded an increased risk of suffering from the development of a blood clot.

It is believed that the chemical drospirenone, which is present in both Yaz and Yasmin, causes health complications in women. The presence of drospirenone in the body elevates levels of potassium, and thus, puts women at a higher risk of developing a blood clot.

Yaz and Yasmin side effects include:

  • Blood clots
  • Stroke
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism

Deep Vein Thrombosis is a serious health condition in which a blood clot forms in a deep vein, most often in a vein in the leg. DVT has been known to cause extreme pain in the location of the blood clot. The danger of DVT is the blood clot migrating to the lungs or brain, causing a more serious and life-threatening condition.

Pulmonary Embolism occurs when a blood clot enters an artery in the lungs, thus obstructing the normal flow of blood to the lungs, and resulting in a lack of oxygen delivery throughout the entire body.

If you or a loved one has suffered from a blood clot caused by the use of either Yaz or Yasmin, you may be eligible to receive compensation for your suffering. To file a Yaz lawsuit or a Yasmin lawsuit, contact our experienced pharmaceutical litigation lawyers at Carey Danis & Lowe.

Controversy Surrounds the FDA’s Decision to Keep Yaz On the Market

By | Pharmaceutical litigation, Uncategorized, Yaz/Yasmin

Published June 20, 2012 on LawsuitInformation.org

The FDA recently mandated that Bayer Pharmaceuticals change the warning labels on two of its most popular birth control pills to reflect recent research relating to blood clots as a result of Yasmin or Yaz. The decision comes in the midst of many ongoing lawsuits against Bayer and generic Yasmin or Yaz manufacturers relating to side effects resulting from Yaz, and has been met with criticism from watchdog groups and other advocacy groups accusing the FDA of not doing enough.

FDA addresses concerns about blood clots as a result of Yaz

In December of last year, an FDA panel of 26 advisors elected to institute the new warnings rather than remove the pills from the consumer market. The vote tallied 15 to 11 in favor of keeping the hormonal birth control pills on the market, but 21 to 5 in favor of instituting stronger warnings about blood clots. Panel members reasoned that the drugs should be kept on the market because the benefits they offer outweigh the possible risks.

In crafting the language of the new warning labels, the FDA has required that they “report that some epidemiologic studies reported as high as three-fold increase in the risk of blood clots for drospirenone-containing products [(the active ingredient in Yasmin and Yaz)] whereas other epidemiological studies found no additional risk.” However, this decision remains controversial as several women’s advocacy groups have pointed out that some of the studies falling in the latter category received funding from Bayer or other contraceptive industry players, and thus may not have been objective, and the results therefore unreliable.

Further adding to the controversy, it has since been discovered that four of the twenty-six FDA panel members had previous affiliations with manufacturers of contraceptives containing drospirenone. The compromising nature of this potential conflict of interests compelled the watchdog group Project on Government Oversight to advocate for a new review and vote on the continued sale of contraceptives like Yasmin and Yaz. Further, on March 9, 2012 a group of four women’s advocacy organizations sent a letter to FDA Commissioner Margaret Hamburg voicing concern about the administration’s decision to keep the drugs on the market.

Many women have been filing a Yasmin lawsuit

As the federal regulatory controversy over Yasmin and Yaz unfolds, plaintiff after plaintiff continues to file a Yaz lawsuit against Bayer and generic Yaz manufacturers alleging health complications like blood clots. Almost 7,000 of these lawsuits have been consolidated into an Illinois multi-district litigation under presiding Judge David R. Herndon. Judge Herndon has actively encouraged parties to seek resolution outside of court by pushing back the initial trials several times.